Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0XS4X
|
||||
| Former ID |
DIB015991
|
||||
| Drug Name |
Ibodutant
|
||||
| Synonyms |
MEN-15596; Tachykinin NK2 receptor antagonist (irritable bowel syndrome), Menarini
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Irritable bowel syndrome [ICD9: 564.1, 787.91; ICD10:A09, K58, K59.1] | Phase 3 | [1], [2] | ||
| Company |
The Menarini Group
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C37H48N4O4S
|
||||
| InChI |
InChI=1S/C37H48N4O4S/c1-26-9-10-30-23-33(46-32(30)21-26)35(43)40-37(15-5-6-16-37)36(44)39-31(22-27-7-3-2-4-8-27)34(42)38-24-28-11-17-41(18-12-28)25-29-13-19-45-20-14-29/h2-4,7-10,21,23,28-29,31H,5-6,11-20,22,24-25H2,1H3,(H,38,42)(H,39,44)(H,40,43)/t31-/m1/s1
|
||||
| InChIKey |
YQYSVMKCMIUCHY-WJOKGBTCSA-N
|
||||
| CAS Number |
CAS 522664-63-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | NK-2 receptor | Target Info | Antagonist | [3] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Reactome | G alpha (q) signalling events | ||||
| WikiPathways | Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02320318) 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D). U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2117). | ||||
| REF 3 | Antagonist profile of ibodutant at the tachykinin NK2 receptor in guinea pig isolated bronchi. Eur J Pharmacol. 2013 Oct 24. pii: S0014-2999(13)00788-7. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.